The tumor suppressor protein p53 is emerging as a central regulator of homologous recombination (HR) processes and DNA replication. P53 may downregulate HR through multiple mechanisms including the reported associations with the Rad51 and Rad54 recombinases, and the BLM and WRN helicases. Here, we investigated whether the interaction of p53 with human replication protein A (RPA) is necessary for the regulation of HR. By employing a plasmid-based HR assay in p53-null H1299 lung carcinoma cells, we studied the HR-suppressing properties of a panel of p53 mutants, which varied in their ability to interact with RPA. Both wild-type p53 and a transactivation-deficient p53 mutant (L22Q/W23S) suppressed HR and prevented RPA binding to ssDNA in vitro and in vivo. Conversely, p53 mutations that specifically disrupt the RPA-binding domain, while not compromising p53 transactivation function (D48H/D49H and W53S/ F54S), did not affect HR. Suppression of HR was also not seen with missense mutations in the p53 core domain (His175 and His273), which retained the ability to interact with RPA, suggesting that the disruption of additional binding interactions of p53, for example, with Rad51 or recombination intermediates, also impacts on HR. We hypothesize that sequestration of RPA by p53 at the sites of recombination is one means by which p53 can inhibit HR processes. Our data support and extend the previously formulated 'dual model' of p53's role as guardian of the genome.
Introduction
Homologous recombination (HR) is a fundamental mechanism which is involved in multiple processes of DNA metabolism Thompson and Schild, 2001; Bishop and Schiestl, 2003) . Through its roles in meiosis and genetic evolution, HR can contribute to genomic variability. Constituting one out of two principal pathways for the repair of exogenous and endogenous DNA double-strand breaks, HR serves to maintain genetic stability. HR is implicated in the repair of DNA crosslinks such as those produced by various chemotherapeutic agents and in re-establishing DNA synthesis at stalled or broken replication forks (Dronkert and Kanaar, 2001; Alberts, 2003) . HR may also offer an alternative pathway to maintain functional telomere length (reviewed in Kass-Eisler and Greider, 2000) . From its diverse roles in DNA metabolism, it follows that HR must be tightly regulated. Increased or deregulated HR may result in genetic rearrangements and loss of heterozygosity, and thus likely plays an important role in carcinogenesis (Wiese et al., 2001; Bishop and Schiestl, 2003) .
The p53 tumor suppressor, also named a 'guardian of the genome' (Lane, 1992) , plays a pivotal role in the maintenance of genomic stability and suppression of cellular transformation. Accordingly, wild-type p53 function is disrupted by genetic mutations or inactivation of upstream or downstream pathways in the majority, if not all, human tumors (Levine, 1997; Sionov and Haupt, 1999) . Over the last few years, p53 has emerged as a multifunctional regulator, which is at the center of several pathways involved in cell-cycle control, apoptosis, and DNA repair. P53 becomes activated in the cellular stress response, which involves sequence-specific DNA binding via the core domain (amino acids 100-300) (Prives et al., 1994) and recruitment of a protein complex that participates in transcriptional activation of downstream genes to the p53 N-terminus (amino acids 1-63) (Candau et al., 1997) . As p53 efficiently regulates its downstream genes only in the form of a tetramer, an intact tetramerization domain (amino acids 325-356) is required for transactivation-dependent functions (Prives et al., 1994) , while the C-terminus may play a regulatory role (amino acids 356-393) (Hupp et al., 1992; Halazonetis et al., 1993) .
Recently, p53 has been established as a novel regulator of DNA recombination and replication Bertrand et al., 1997; Mekeel et al., 1997; Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Willers et al., 2000a, b; Gottifredi et al., 2001 ; Akyu¨z et al., 2002; Boehden et al., 2003; Linke et al., 2003) . The data from our own and other laboratories have demonstrated that p53 downregulates spontaneous and double-strand break-induced HR, and this may be one mechanism by which p53 maintains genomic integrity. Furthermore, p53 has been implicated in suppressing HR at arrested replication forks Saintigny and Lopez, 2002) . Thus, both p53-mediated G1 cell-cycle arrest and inhibition of replication-associated HR may serve to prevent cell proliferation in the presence of unrepaired DNA damage.
The mechanisms by which p53 regulates HR are just beginning to be elucidated. In multiple reports, HR regulation has been dissociated from p53's role in the transcriptional activation of downstream target genes (Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Willers et al., 2000b; Boehden et al., 2003; Linke et al., 2003) . Consistent with these data, transcriptionally inactive p53 accumulates in the S phase following replication arrest (Gottifredi et al., 2001 ). It appears that p53 can affect HR through various direct protein and DNA interactions: (i) binding and inhibition of the Rad51 recombinase as well as Rad54 (Stu¨rzbecher et al., 1996; Linke et al., 2003) , (ii) interaction with and modulation of the activities of the BLM and WRN helicases, which may affect HR at arrested replication forks (Yang et al., 2002; Sengupta et al., 2003) , (iii) binding to HR intermediates and Holliday junctions (Lee et al., 1997; Dudenho¨ffer et al., 1998 Dudenho¨ffer et al., , 1999 Su¨sse et al., 2000) , and (iv) exonucleolytic proofreading of misrepaired heteroduplexes (Su¨sse et al., 2000; Janz and Wiesmu¨ller, 2002) . Structural analysis has shown that inhibition of HR is dependent upon intact core and tetramerization domains of p53 (Dudenho¨ffer et al., 1999; Su¨sse et al., 2000; Akyu¨z et al., 2002; Boehden et al., 2003) , while the C-terminus appears to be dispensable for this effect (Dudenho¨ffer et al., 1999; Willers et al., 2000b) . Mutation of residues 22 and 23 within the N-terminal transactivation domain does not affect HR, but other domains important for HR regulation have not been identified in vivo (Akyu¨z et al., 2002; Boehden et al., 2003) .
Replication protein A (RPA) is a heterotrimeric single-stranded (ss) DNA-binding protein, which is involved in multiple aspects of DNA metabolism, including replication and HR (reviewed in Iftode et al., 1999) . Human RPA is a complex composed of three subunits of 70, 34, and 14 kDa. The DNA-binding activity of RPA is associated with the largest 70 kDa RPA1 subunit, with an additional weak DNA-binding domain residing on the 32 kDa RPA2 subunit, while the smallest 14 kDa RPA3 contributes to stabilization of the heterotrimeric RPA complex (Philipova et al., 1996; Bochkarev et al., 1997; Bochkareva et al., 1998) . RPA1 and 2 are also involved in the interaction with other proteins, which may be influenced by cell cycle and DNA damage-dependent phosphorylation of the RPA2 subunit (Brush et al., 1994; Henricksen et al., 1994) . RPA binds with high affinity to ssDNA, with a preference for polypyrimidine tracts in vitro (Kim et al., 1992) , stabilizing ssDNA intermediates, and removing secondary structures from ssDNA regions. p53 interacts with RPA and the interaction site has been mapped to the N-terminal domain of p53 in vivo (Dutta et al., 1993; Leiter et al., 1996) . By binding the RPA1 subunit, p53 prevents RPA binding to ssDNA. However, the functional consequences of the p53-RPA interaction have not been defined. In the present study, we investigated whether the interaction of p53 with RPA is necessary for the inhibition of HR by p53.
Results

Properties of wild-type p53 and N-terminal mutants in regard to cell viability and transactivation function
To study the role of p53-RPA binding for the regulation of HR in vivo, we employed previously characterized N-terminal mutants of p53 (Leiter et al., 1996; Lin et al., 1996) . The RPA-binding domain is represented by aromatic amino acids flanked by negatively charged residues, which are conserved among various RPA interacting proteins (Leiter et al., 1996) . The D48H/D49H (48,49) and W53S/F54S (53,54) mutations of the p53 N-terminus have been found to specifically disrupt RPA binding, but do not significantly alter transactivation activity. By contrast, mutations of residues 22 and 23 (L22Q/W23S) abolish the transactivation function and growth-suppressive effect of p53 while maintaining RPA binding (Leiter et al., 1996) . Importantly, all these mutations are located outside the reported binding regions with Rad51, which have been mapped to amino acids 94-160 and 264-315 of p53 (Buchhop et al., 1997) and may be important for a direct suppressive effect of p53 on Rad51-mediated HR.
Growth suppression and cytotoxicity resulting from exogenously expressed wild-type p53 can be a significant problem in the functional analysis of HR in vivo (Blagosklonny et al., 1998; Willers et al., 2000a Willers et al., , 2002 . Therefore, we sought to establish transfection conditions that afforded nontoxic low-level expression of wild-type p53 as well as the N-terminal mutants in the p53-null H1299 lung carcinoma line. Co-transfection of 525 ng of a wild-type p53 expression vector with a green fluorescent protein (GFP) expressing plasmid at a ratio of 7 : 1 resulted in notable cell death and an associated threefold decrease in the number of GFP-expressing cells over a 48-h post-transfection period (Figure 1a ). By comparison, there was little reduction in the number of GFP-positive cells when an empty control vector was co-transfected. However, when we reduced the amount of p53 vector by threefold to 175 ng, cell toxicity was eliminated and the time course of GFP expression was comparable for all transfections, that is, vectors for empty control, wild-type p53, and N-terminal mutants ( Figure 1a ). Under these conditions, transfection frequencies were stable, ranging from 32 to 43%. Low-level expression of exogenous p53 protein was verified by p53-RPA interaction suppresses homologous recombination LY Romanova et al Western blotting at multiple time points (Figure 1b) . Eventually, 60 h after transfection, there was complete loss of p53 expression.
To verify the transactivation properties of the Nterminal mutants in our H1299 model cell line, expression vectors were co-transfected with reporter constructs that carry the CAT reporter downstream of a p53 consensus sequence. Consistent with these and previous findings (Leiter et al., 1996; Lin et al., 1996) , wild-type p53 efficiently activated reporter transcription (Figure 1c ). The p53(48,49) and p53(53,54) mutants retained 70-80% of the wild-type p53 transactivation activity, compared with p53(22,23), which showed no more than 25-30% of wild-type activity. Western blot analysis showed that wild-type p53, p53 (48, 49) , and p53(53,54), but not p53(22,23) induced expression of endogenous p21
Waf1 when transiently transfected into the H1299 cells (Figure 1d ).
Intact RPA-binding sites are necessary for suppression of HR by p53
To determine the impact of wild-type p53 and the N-terminal mutants on HR in a chromosomal context, we employed a chromosomal targeting system using the plasmid substrates pD2-puro and pD3 ( Figure 2a) . We have established this assay previously to measure the effect of BRCA2 on HR (Xia et al., 2001) . Each pD2puro and pD3 plasmid carries a copy of the bacterial gpt gene that is inactivated by a 5 0 -or 3 0 -deletion, respectively. Homology-mediated recombination between these gene copies, which would primarily involve a de novo DNA synthesis-dependent mechanism, can reconstitute a functional gpt gene and confer resistance to XHATM selection in a colony formation assay. H1299 cells with stably integrated pD2puro were transiently co-transfected with the donor plasmid pD3, together with a p53 expression vector or an empty control vector, and p53 protein expression was verified by Western blotting. For the cells transfected with the control vector, selection under XHATM yielded a mean homologous gene-targeting frequency of 23.9 Â 10 À4 ( Figure 2b ). Wild-type p53 and the p53(22,23) mutant suppressed HR by approximately 14-and ninefold, respectively. Despite exhibiting almost wild-type-like transactivation activity, inhibition of HR by p53(48,49) and p53(53,54) was nonsignificant at 1.4-and 1.7-fold, respectively. Therefore, our data suggest that suppression of HR is independent of p53's transactivation activity, as reported (Boehden et al., 2003; Linke et al., 2003) , but requires an intact RPA-binding site. It has already been demonstrated previously that p53 can directly interact with RPA and prevent RPA binding to ssDNA using the purified proteins (Dutta et al., 1993) . To verify the in vitro properties of wild-type p53 and the N-terminal mutants with respect to RPA binding in our system, increasing concentrations of GST, GST-conjugated wild-type p53 or the mutant fusion proteins were incubated with crude lysates of H1299 cells, which express high levels of endogenous RPA. The RPA protein from these extracts efficiently bound p53 and p53(22,23), but not p53(53,54) ( Figure  3a,b) . Upon further incubation with ssDNA-bound cellulose, wild-type p53 and p53(22,23) diminished RPA binding to ssDNA, but p53(53,54) did not ( Figure 3c ). The reduction of RPA-ssDNA binding appeared to be a direct function of the p53-RPA protein ratio, because increasing the amounts of wild-type p53 or p53(22,23) protein in the reaction further lowered the detected levels of bound RPA (Figure 3c ). Thus, we concluded that inhibition of RPA binding to ssDNA by p53 is independent of p53 transcriptional activation activity, but requires direct p53 binding with RPA.
We next investigated whether wild-type p53 and the N-terminal mutants, which were expressed in H1299 cells at low levels under these experimental conditions, were capable of sequestering endogenous RPA. To assess the in vivo pattern of p53 binding to RPA, H1299 cells were transiently transfected with the low levels of p53 expression vectors or the control vector as described above. Wild-type p53 and p53(22,23) co-immunoprecipitated with RPA, but p53(48,49) or p53(53,54) did not (Figure 3d ), a pattern similar to that seen for the in vitro interaction. In a set of parallel experiments, we also cotransfected the p53 expression vectors or the control After immunoprecipitation with anti-RPA2 antibody, the amount of RPA1-bound radioactivity was analysed by autoradiography on nondenaturing polyacrylamide gels. RPA2 and p53 proteins levels were analysed by Western blots using anti-RPA2 antibodies or polyclonal anti-p53 antibody after protein resolution on denaturing polyacrylamide gels p53-RPA interaction suppresses homologous recombination LY Romanova et al vector together with radioactively labeled doublestranded oligonucleotides with either complementary sequences (MATCH), or one that contains a 10-nucleotide mismatched region (MIS) to create a ssDNA substrate (Figure 3e ). This oligonucleotide design has been employed previously to study the binding of RPA to ssDNA in vitro (Lao et al., 1999) . We demonstrated that little, if any, radioactivity bound to RPA1 when MATCH oligonucleotide was co-transfected with either control vector or wild-type p53. In contrast, the labeled oligonucleotide bound to RPA1 in the cells transfected with the combination of MIS and the control vector. The amount of RPA-bound radioactivity was decreased in the cells expressing low levels of wild-type p53 and p53(22,23), but not p53(48, 49) or p53(53,54). Importantly, we have observed similar uptake of transfected DNA in all parallel experiments. We concluded that low levels of p53 could disrupt RPA binding to ssDNA in vivo. Moreover, similar to the results obtained in vitro, inhibition of RPA binding to ssDNA is independent of p53 transactivation activity, but requires direct physical interaction with RPA.
Mutation of the p53 core domain compromises regulation of HR but not RPA binding
We employed expression vectors for two p53 missense mutations as they occur in human tumors, that is, the conformational mutant p53-His175 and the DNA contact mutant p53-His273. These mutants have been previously reported to lack binding to HR intermediates and fail to suppress HR (Dudenho¨ffer et al., 1999; Su¨sse et al., 2000) . Both mutants co-immunoprecipitated with RPA to a similar degree as wild-type p53 ( Figure 4a ). As perhaps expected, wild-type p53 led to a more than 10-fold suppression of HR, whereas the missense mutants affected HR frequencies by less than twofold (Figure 4b ). Therefore, RPA binding is necessary, but not sufficient for the inhibition of HR. Together, the data suggest that high-affinity binding to model recombination intermediates by RPA is inhibited by p53, and is likely to be an important requirement for the efficient inhibition of HR by p53. (Buchhop et al., 1997) . Another class of p53 mutants, His175 and His273, that represent common tumor missense mutations, have retained RPA-binding capacity similar to wild-type p53, but were unable to inhibit HR. Thus, RPA binding is not sufficient for the inhibition of HR by p53. It was previously reported that high-affinity p53 binding to recombination intermediates is required for inhibition of HR and both His175 and His273 mutants are deficient in this function (Dudenho¨ffer et al., 1999; Su¨sse et al., 2000) , which suggests that p53 binding to recombination intermediates is needed for RPA-dependent inhibition of HR by p53. In contrast, certain core mutations such as those found with the temperature-sensitive murine Val135 or human Ala143 mutant proteins may result in relative minor structural changes and therefore still allow for suppression of HR in conjunction with their effect on RPA function (Willers et al., 2000b ). An alternative mechanism by which core mutations may lose the ability to downregulate HR is the disruption of binding to and inhibition of Rad51 function.
As p53 can sequester RPA and prevent its binding to ssDNA in vitro, it is a conceivable mechanism underlying the suppression of HR by p53. One conceptual problem with this mechanism may involve the relatively large amounts of cellular RPA protein that exist in cells in relation to p53. However, by imitating the high RPA/ p53 ratio in cells, we demonstrated that wild-type p53 even at low concentrations is capable of inhibiting RPA binding to ssDNA in vivo. Moreover, inhibition of RPA binding to ssDNA is independent of p53 transcriptional activation activity, but requires intact RPA binding. This suggests that RPA binding to ssDNA in vivo could be regulated by p53 through the same mechanism that was demonstrated in vitro. Our data are supported by the finding of Treuner et al. (1998) , who demonstrated that only a small fraction of RPA is bound to ssDNA within cells. Given the co-localization of p53 with Rad51 and associated proteins in subnuclear foci during the S phase (see below), it is conceivable that the inhibitory effect of p53 on RPA is more likely occurring locally at recombinogenic DNA intermediates.
The recombination substrates pD2puro and pD3 employed in this study contain copies of the bacterial gpt gene harboring large 5 0 and 3 0 deletions, respectively. Restoration of a functional copy of the gene as a result of HR would primarily require a mechanism involving de novo DNA synthesis. Therefore, we suggest that there may be several stages that involve the ssDNA-binding property of RPA. The secondary structure of ssDNA is relaxed as a result of RPA binding, which is known to facilitate the assembly of the Rad51/Rad52-containing pre-synaptic nucleoprotein complex onto the 3 0 DNA strand at the initial stage of the recombinational process (Park et al., 1996; Sigurdsson et al., 2001 ). An invading 3 0 ssDNA end may serve as a primer for the leadingstrand DNA synthesis. Initiation of recombinationmediated DNA synthesis involves nearly all the components of normal DNA replication and RPA seems to play a central role in this process (Yuzhakov et al., 1999) . For instance, RPA-ssDNA binding is required for loading of RFC onto a 3 0 ssDNA primer at the initial stage of DNA replication. Recruitment of other components of the polymerase d holoenzyme complex is driven by a series of competition-based protein-RPA switches. RPA-ssDNA-binding properties are also important for synthesis of the lagging DNA strand, which was shown to occur during recombination (Holmes and Haber, 1999) . For example, ssDNA-bound RPA stimulates activity and processivity of polymerase a and governs Fen1-dependent removal of RNA primers from Okazaki fragments (Braun et al., 1997; Bae et al., 2001) . Finally, while bound to ssDNA, RPA participates in the elongation stage of DNA synthesis (Walther et al., 1999) . Therefore, preventing RPA binding to ssDNA by p53 could be a very effective way of inhibiting DNA synthesis-dependent HR.
A complex role of p53 in the regulation of HR and replication p53 is emerging as a central regulator of HR and replication, interacting and co-localizing with a variety of proteins involved in HR processes. Rad51, the homologous pairing and strand exchange protein, has been described to cooperate with p53 in the regulation of the initial step of HR in vitro (Su¨sse et al., 2000; Janz and Wiesmu¨ller, 2002) . p53 was also reported by Stu¨rzbecher et al. (1996) to bind directly to Rad51 and block the activity of the bacterial Rad51 homolog, RecA. A recent report from the Harris and Stu¨rzbecher labs found that p53 can be co-immunoprecipitated with Rad51 using normal human fibroblasts. Moreover, inhibition of Rad51 function abrogated the p53-mediated suppression of plasmid-based HR . Recently, p53 has also been reported to interact with Rad54 both in vitro and in vivo .
P53 and Rad51 co-localize with the BLM helicase in nuclear foci that presumably form at sites of replication fork collapse . BLM may recruit p53 to sites at which HR is favorable but not necessarily desirable. Inhibitory interactions of p53 with Rad51 and/or Rad54 may assist in downregulation of inappropriate HR , but the precise mechanisms of how the relationship between p53, RPA and Rad51/Rad54 affects HR remain to be elucidated. In addition, p53 could directly modulate the antirecombinogenic function of the BLM and WRN helicases (Yang et al., 2002; Sengupta et al., 2003) . It will be important to understand which types of HR are affected by p53. Wiesmu¨ller and colleagues have suggested that p53 preferentially suppresses short-tract gene conversions, which may serve to prevent error-prone exchange processes (Akyu¨z et al., 2002) . Another preferred target of p53 could be heteroduplexes that contain mismatches (Dudenho¨ffer et al., 1998; Janus et al., 1999; Su¨sse et al., 2000) . Consistent with such a function, p53 has been found to possess 3 0 -5 0 exonuclease activity and to colocalize with the MSH2 mismatch repair protein (Mummenbrauer et al., 1996; Zink et al., 2002) . p53 has also been reported to co-localize with Mre11 and BRCA1, both of which function in HR, but the functional consequences of these associations remain to be established (Carbone et al., 2002; Zink et al., 2002) .
In addition, multiple observations link p53 directly to DNA replication. P53 co-localizes with DNA synthesis and the replication apparatus (Huang, 1998) , as well as viral replication sites (Wilcock and Lane, 1991) . P53 is expressed in parallel to DNA synthesis when cells reenter the cell cycle (Mosner and Deppert, 1994) , and it migrates into the nucleus in the S phase (Shaulsky et al., 1990; Martinez et al., 1991) . Replication of damaged DNA is blocked by p53 in vitro (Zhou and Prives, 2003) . Following treatment with the inhibitor of replication elongation, hydroxyurea, transcriptionally inactive p53 accumulates in the S phase (Gottifredi et al., 2001) . Consistent with these findings, p53 downregulates HR when replication elongation is blocked (Janz and Saintigny and Lopez, 2002) .
A dual model of p53 in the maintenance of genomic stability
We have found that mutation of residues 22 and 23 in the N-terminal transaction domain of p53, which binds to components of the transcription machinery, does not (Boehden et al., 2003; Linke et al., 2003) . Thus, these results clearly establish the dissociation of HR regulation from p53's traditional role in the G1 cell-cycle checkpoint and as a transcriptional activator (Dudenho¨ffer et al., 1999; Saintigny et al., 1999; Willers et al., 2000b) . Furthermore, the data also suggest that the effect of p53(22.23) is not restricted to a particular HR assay or chromosomal plasmid substrate integration site. Taken together, the data support and extend the previously formulated 'dual model' of p53 functioning as a 'guardian of the genome' Willers et al., 2000b) . In addition to the well-documented cellular stress responses mediated by activated p53 that usually require sequence-specific DNA binding and transcriptional activation function, the model postulates a direct protein-mediated suppression of HR by the 'latent' protein form of p53, which is generally considered inactive for transcriptional activation. Here, we have identified the p53-RPA protein interaction as one means to regulate HR. Consistent with this dual regulatory model, p53 activation in response to DNA damage has been shown to be accompanied by the release of RPA protein (Abramova et al., 1997; Liu et al., 2000) . The p53 tumor suppressor is emerging as a multifunctional regulator that is integrated into an intricate network of cell-cycle control and DNA metabolism. Prevention of potentially mutagenic DNA synthesis in the presence of endogenous or exogenous DNA damage may be regulated by p53 either by transactivationmediated initiation of cell-cycle arrest or by a more direct RPA-dependent halting of replication. Whether the p53-dependent regulation of HR contributes to p53's role as a tumor suppressor will be an important subject for future investigations.
Materials and methods
Cell lines, reagents, and plasmids constructs
The NCI-H1299 line is a non-small-cell lung carcinoma cell line and was obtained from ATCC. H1299 cells harbor a partial homozygous deletion of both alleles of the p53 gene and are functionally p53-null. Cells were maintained in complete RPMI 1640 medium with added 10% fetal bovine serum. The recombination substrates pD2puro and pD3 are derivatives of pSV2gpt plasmid and have been described before (Xia et al., 2001) . pD2puro has a 440-bp deletion removing the SV40 early promoter and the first 120 nucleotides of the gpt reporter gene, whereas pD3 carries a 1358-nucleotide deletion that includes the 3 0 end of the gene (Figure 2a ). These recombination substrates share 460 bp sequence homology within the gpt coding region. pD2puro expresses a puromycin resistance gene to allow for chromosomal integration in mammalian cells. A panel of CMV-based p53 plasmid expression vectors was employed: wild-type p53 was expressed from pC53-SN3, p53 (22,23) and p53(48,49) from a pRc/CMV vector, and p53(53,54) from a pcDNA3-based vector (Leiter et al., 1996; Lin et al., 1996; Willers et al., 2000a) . GTK-based constructs were used for the bacterial expression of GST or GST-conjugated fusion proteins p53(22,23) and p53(53,54), and pGEX-2T contained GSTwild-type p53 fusion protein (Huibregtse et al., 1991; Leiter et al., 1996) . An expression vector for green fluorescent protein (pEGFP-N1, Clontech) was employed to standardize the plasmid uptake frequency in the tested cells. Qiagen kits were used for plasmid isolation and purification. pEGFP-N1 and pD3 expression constructs were further purified two times in cesium chloride gradients.
Cell viability testing
H1299 cells were transiently transfected in six-well plates using the lipofectamine plus procedure (Gibco, BRL). Transfections utilized 25 ng pEGFP in combination with 175 ng per well of either a vector control, wild-type p53, p53 (22,23), p53(48,49) or p53(53,54) . This ratio served to assure that p53 protein expression would occur in every cell taking up the pEGFP plasmid. The viability of the expressing GFP in combination with one of the expression constructs was assessed 12 and 60 h later by FACS scanning. The data are presented as a percentage change in GFP-expressing cells during this time interval. Data were analysed using STATIATICA (Statistica, StatSoft, Inc., Tulsa, OK 74104). The elimination rate of GFP-expressing cells in the population expressing empty control vector was compared with the populations expressing wild-type or mutant p53 using nonparametric w 2 tests.
Homologous recombination assay
Single-cell-derived H1299 subclones carrying chromosomally integrated pD2puro were screened for their proficiency to undergo HR. A representative subclone was selected and subsequently transiently transfected in 100-mm dishes with 50 ng of pD3 and 350 ng of one of the p53 expression plasmids or an empty control using Lipofectamine Plus (Invitrogen). After 60 h, the cells were plated into 75 cm 2 flasks at concentrations of 10 6 and 2 Â 10 6 . After 24 h, XHATM was added (xanthine, hypoxanthine, aminopterin, thymidine, and mycophenolic acid at 20, 13.6, 0.17, 3.87, and 25 mg/ml, respectively; all Sigma). After 3 weeks, XHATM-resistant colonies containing 50 or more cells were stained with methylene blue and counted. The frequency of HR was calculated as the number of XHATM-resistant colonies divided by the number of cells seeded and corrected for plating efficiency.
Transcriptional activation assay
We used p50-2 or pWWP-CAT constructs that express the chloramphenicol acetyl-transferase gene (CAT) downstream of a p53-binding consensus sequence or the sequence derived from the wild-type p21
Waf1 promoter (Willers et al., 2000b) . In all, 3 Â 10 6 H1299 cells were transiently transfected with p50-2 or pWWP-CAT in combination with one of the p53 expression vectors. After 24 h, the cells were lysed in 1 ml of the Reporter Lysis buffer (Promega). The lysates (5 or 10%) were mixed with 1 mM chloramphenicol (Sigma) and 0.025 mM 14 C-butyrylCoA (0.1 mCi; NEN-DuPont), overlaid with 5 ml of Econofluor (NEN-DuPont) and incubated for 1 h at 371C. CAT expression was assessed by incorporation of the 14 C-labeled acetyl group into chloramphenicol, which can be dissolved in nonaqueous Econofluor. 14 C present in the Econofluor fraction was measured by a liquid scintillation counter (Packard LVP164000 Series).
Protein-binding assays
In all, 400-600 ng of GST and 200-300 ng of GST-conjugated fusion proteins expressing wild-type p53, p53(22.23), or p53(53.54) were incubated for 30 min with 70 mg of S100 crude cell extract. In the ssDNA-binding experiments, this incubation was followed by 1 h incubation with poly(dT)-bound cellulose (Stratagene). RPA, immobilized by ssDNA-bound cellulose, was analysed by Western blots using anti-RPA2 antibody (Oncogene Science). S100 extract was prepared from 5 Â 10 5 H1299 cells as described earlier (Stillman and Gluzman, 1985) . Briefly, 10 min incubation in 5 ml of hypotonic buffer (20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES-KOH, pH 7.5), 5 mM KCl, 1.5 mM MgCl 2 , 0.1 mM dithiothreitol) was followed by sonication and further 10 min centrifugation at 10 5 g. The supernatant was removed and used for in vitro ssDNA-binding assay.
In vivo RPA binding to ssDNA/dsDNA
We used a double-stranded version of a 40 bp oligonucleotide that was previously reported for in vitro analysis of RPA binding to ssDNA (Lao et al., 1999) . Briefly, the oligonucleotide derived from SV40 origin, 5 0 -CTCCAAAAAAGCCT CCTCACTACTTCTGGAATAGCTCAGA-3 0 , was labeled with [g-32 P]ATP by T4 polynucleotide kinase. The labeled DNA was annealed to an equal amount of the complimentary sequence, 5 0 -TCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAG-3 0 , creating a double-stranded oligonucleotide (designated, MATCH). The 40 bp fragment with 10 bp mismatched region (MIS) was made by annealing a labeled oligonucleotide with another one, 5 0 -TCTGAGCTATTCCAGcgacgacactGAGGCTTTTTTGGAG-3 0 , in which small letters indicate the bases that have been changed to noncomplimentary bases. After resolving the annealed mixture on 15% polyacrylamide gels, the double-stranded fragment was cut from the gel, purified using phenol-chloroform mixture, precipitated with ethanol, and further used for cell transfection experiments. H1299 cells were transfected with one of the p53 expression vectors in combination with 10 ng of labeled MATCH or MIS nucleotide using the earlier established conditions. After 12 h, RPA was immunoprecipitated from the cells with monoclonal anti-RPA2 antibody, resolved on nondenaturing polyacrylamide gels and the amount of oligonucleotide bound to RPA1 subunit was assayed by radiography.
Immunoprecipitation and Western blots
Immunoprecipitation and Western blots were performed as described previously (Romanova et al., 1999) . The buffer containing 10 mM Tris-HCl, pH 7.4; 20 mM sodium chloride; 0.5 mM EDTA; 0.5 mM EGTA; 0.01% NP40; 10 mg/ml aprotinin; 10 mg/ml leupeptin, and 500 mM PMSF was used for immunoprecipitation. GammaBindRG Sepharose s (Pharmacia) beads, polyclonal anti-p53 antibodies (Santa Cruz), monoclonal anti-p53, Pab1801 (Pharmingen), monoclonal anti-RPA1 (Oncogene Science), anti-RPA2 (Oncogene Science) and anti-p21Waf1 (Pharmingen) antibodies were used for immunoprecipitation and for Western blots. Goat antirabbit or anti-mouse IgG conjugated with horseradish peroxidase (Amersham) was used as secondary antibodies.
